drug discovery development News
-
The `Network for Pharma Solutions` (NetPhaSol) starts campaign for networking and cooperation
NetPhaSol, the nationwide network of 30 companies and 20 research institutions covering the entire value chain in drug discovery and development, is launching its campaign for networking and cooperation. Are you looking for qualified partner for your project? Are you looking for special expertise for a technological solution? Then NetPhaSol is the right partner for you. Access to the network is ...
-
Accelerating Lupus Drug Discovery & Development - Fireside Chat with Experts in SLE Research
Genuity Science is bringing together a distinguished panel of experts from academia, research and industry to discuss opportunities and advancements in developing better treatments for systemic lupus erythematosus (SLE). SLE is a chronic and relapsing autoimmune disease characterized by a break-down of self-tolerance that leads to tissue inflammation and multiorgan damage. SLE is extremely ...
-
Cell Metric X Captures Distinguished Nomination for ‘Best New Drug Discovery & Development Product’ In Scientists’ Choice Awards
Laboratory scientists across the world are being invited to have their say in the 2024 Scientists’ Choice Awards®. The annual Scientists’ Choice Awards celebrate the most innovative and effective technologies of the past year and provide scientists worldwide with the opportunity to acknowledge the instruments, assays, tools, or consumables that have made the most difference to ...
-
Valo Health to Participate in UBS Biotechnology Virtual Private Company Symposium
Valo Health, Inc (“Valo”), the technology company focused on transforming the drug discovery and development process using human-centric data and artificial intelligence, announced that David Berry, founder & CEO of Valo will present at the UBS Biotechnology Virtual Private Company Symposium on September 22, 2022 from 11:30 AM EST to 11:55 AM EST. About Valo Health Valo Health, ...
-
Valo Health To Participate in Piper Sandler`s 34th Annual Healthcare Conference
Valo Health, Inc ("Valo"), the technology company focused on transforming the drug discovery and development process using human-centric data and artificial intelligence, today announced that its founder & CEO, David Berry, will present at Piper Sandler's 34th Annual Healthcare Conference at The Lotte New York Palace, New York, NY, on Thursday, December 1, 2022 at 8:10 AM (Kennedy 1, 4th ...
-
Genome Biologics secures up to €9.8M in equity funding from the EIC Accelerator to accelerate development of its clinical programs for the prevention of cardiotoxicity and heart damage – an area of huge unmet need within the EU and globally
Genome Biologics UG, Frankfurt, Germany, today announced that they have been awarded up to 9.8 million euros of equity funding through the European Innovation Council (EIC) Accelerator program to accelerate their breakthrough innovations in cardiovascular drug discovery and development. Cardiovascular diseases account for the majority of mortality and disability globally, accounting for 32% of ...
-
CytoReason and Pfizer Extend Collaboration to Leverage Machine Learning in Drug Development
TEL AVIV, Israel, Feb. 10, 2022 /PRNewswire/ -- CytoReason, a leading developer of computational disease models for efficient drug discovery and development, today announced the extension of its collaboration agreement with Pfizer. "The extension of our collaboration with CytoReason will build upon our existing data science capabilities, and further enhance our ability to make data-driven ...
By CytoReason
-
Webinar #4: The CAM Assay: From Efficacy/Toxicity Studies to Mechanisms of Action Analysis
Webinar Description: Understanding the mechanisms of action of new drugs is a key success factor for efficient drug discovery. It’s necessary for: Anticipating problems relating to clinical safety Determining the site of interaction between a drug and a receptor Identifying which patients will respond to a given treatment Improving drug dosing Considering combinations or ...
-
CytoReason Expands Its Reach in Asia, Forging Commercial Alliance with Helixrus to Leverage Machine Learning in Drug Development for Korean Drugmakers
TEL AVIV, Israel and SEOUL, South Korea, April 12, 2022 /PRNewswire/ -- CytoReason, a leading developer of computational disease models for efficient drug discovery and development, announced today the signing of a commercial partnership with Helixrus, a leading Korean company focused on biological big data and multi-omics. The partnership will see Helixrus represent CytoReason's unique AI ...
By CytoReason
-
CD ComputaBio Introduces AutoDock, a Powerful Molecular Docking Software
CD ComputaBio, a reliable computational biology service provider in New York, is committed to assisting research and trials, as well as providing access to the latest software, technologies, and expertise at competitive prices and with fast turnarounds for researchers. The company is ready to support your molecular docking projects with its innovative AutoDock software. Autodock is an ...
-
Healx launches AI-powered indication expansion partnership with Ono Pharmaceutical Co. Ltd.
Healx, the AI-powered, patient-inspired technology company pioneering the next generation of drug discovery, today announced an exciting partnership with Ono Pharmaceutical Co., Ltd., one of Japan’s largest pharmaceutical companies and a global leader in the field of R&D-orientated drug discovery. The collaboration will leverage Healx’s innovative indication expansion technology ...
By Healx Ltd.
-
MedBiome Announces the Appointment of Shane Climie as Vice-President Business Development
MedBiome, a company specializing in the development of therapeutics targeting the gut microbiome, today announced that Dr. Shane Climie has been appointed as Vice-President of Business Development. In Dr. Climie’s role as Vice President of Business Development at MedBiome Inc. he is responsible for corporate development, strategy and partnering. Dr. Climie is also President of ...
-
Dr. Ryan Gordon joins the Stem Pharm team as Sr. V.P. of Business Development
Dr. Ryan Gordon has joined the Stem Pharm team as Sr. V.P. of Business Development and Commercialization. Gordon brings to Stem Pharm over 20 years of business, R&D, and operational experience in developing and commercializing innovative biopharmaceutical technologies to revolutionize disease treatment and improve patient outcomes. He has been a valued leader at large companies (3M) and ...
-
Ildong’s affiliate gets nod for phase 1b/2a trial of new cancer drug in Korea
Idience Co., a drug discovery and development company affiliated to South Korea’s Ildong Holdings, announced on Monday it has received approval of a phase 1b/2a trial of its investigational cancer drug IDX-1197 from the Ministry of Food and Drug Safety. The company said the new clinical study will evaluate the drug’s safety and efficacy profile in more cancer types than the phase 1a ...
-
CanaQuest Awarded Best Global Medical Cannabinoid Development Company 2023 by UK-based Global Health & Pharma for their 8th Annual Healthcare and Pharmaceutical Program
Canaquest Medical Corp (OTC PINK:CANQF) (the "Company" or "CanaQuest"), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), today announced that it has been awarded the Best Global Medical Cannabinoid Development Company 2023, in its eighth annual Healthcare and Pharmaceutical ...
-
Orion Shares New Data on its Latest Best-in-Class Drug Candidate
Orion Biotechnology Canada Ltd, a drug discovery and development company unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs), today announced that it will be presenting important new data at both LSX World Congress and TIDES USA 2022 conference, taking place this week – May 10-12, 2022. Dr. Oliver Hartley, Orion’s Vice-President Drug Discovery, will present ...
-
Xilis Raises $70 Million Series A Financing to Advance Diagnostic and Drug Discovery and Development Platform Leveraging Proprietary MicroOrganoSphere Technology
Xilis’ MicroOrganoSphere™ (MOS) technology generates thousands of miniature patient- derived tumors that capture the original heterogeneity and microenvironment for therapeutic profiling The company’s platform can deliver personalized precision treatment strategies for patients and accelerate drug discovery and development for pharmaceutical companies Xilis, ...
By XILIS, Inc.
-
VeriSIM Life Earns Frost & Sullivan Competitive Strategy Leadership Award for Best Practices in AI-enabled Preclinical Development Industry
Frost & Sullivan recently assessed the artificial intelligence (AI)-enabled preclinical development industry, and, based on its analysis results, recognizes VeriSIM Life with the 2022 North America Competitive Strategy Leadership Award. The company's core mission is to increase human life expectancy through artificial intelligence-driven biosystem simulations and to personalize patient ...
By VeriSIM Life
-
VeriSIM Life Enters into Collaboration Agreement with Mayo Clinic to Jointly Advance Drug Discovery and Development Programs
VeriSIM Life (VeriSIM) www.verisimlife.com, a leading artificial intelligence (AI)-enabled company providing services to de-risk R&D decision making for breakthrough drug development, today announced that it has entered into a collaboration with Mayo Clinic to improve the preclinical translation of promising drug candidates. “We are excited to expand our common mission and work with ...
By VeriSIM Life
-
JSR, the collaborative research facility "JSR BiRD" in Kawasaki, invites KINS Co., Ltd.
JSR Corporation (Head Office: Minato-ku, Tokyo, Representative Director and CEO: Eric Johnson, JSR Corporation) announced today that it has concluded a facility use agreement with KINS Co., Ltd. (KINS), a company with a database of human microbiome, for the Collaborative Lab, a collaborative research facility for startups, which was established in a new research laboratory at the "JSR Bioscience ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you